• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 10, 2015

View Archived Issues

Amyloid pathology may be transmittable during some surgical procedures

Up until 1985, one treatment for children with growth deficiencies was nonrecombinant human pituitary growth hormone from the pituitary glands of deceased individuals. Such treatment was discontinued when it was discovered that along with growth hormone, the extracts could contain the prion protein that is the cause of Creutzfeldt-Jakob disease (CJD). Read More

Ascletis banks $35M, kicks off phase II HCV IFN trial in Taiwan

SHANGHAI – Hangzhou, China-based Ascletis Inc. received $35 million in venture capital investment and kicked off a Taiwan phase II trial for its interferon-free hepatitis C regimen. Read More

Biogen bets up to $544M on Mitsubishi Tanabe S1P modulator

Seeing broad potential for Mitsubishi Tanabe Pharma Corp.'s oral sphingosine 1-phosphate antagonist MT-1303, Biogen Inc. agreed to pay $60 million up front and up to $484 million in additional milestones for an exclusive license to the phase II program outside Asia. Read More

Breo drops TORCH, fails to extend lives in massive SUMMIT trial

Data from the much-anticipated SUMMIT study failed to show that Relvar/Breo Ellipta (fluticasone furoate/vilanterol) statistically significantly extended the lives of chronic obstructive pulmonary disease (COPD) patients, indicating to investors that the product, dubbed the "son of Advair" likely won't be restoring Glaxosmithkline plc's respiratory disease franchise to its once-great heights. Read More

Japan intensifies efforts to innovate drug development

TOKYO – Japan is reaching out to drug developers from around the world to attract more innovative products and emerge as a regional leader in the field. Read More

Samsung wins nod for Enbrel biosimilar on its home turf

HONG KONG – Marking another step in its path to profitability, South Korea's Samsung Bioepis Co. Ltd. reported a first approval in its home market for a biosimilar – Brenzys – based on Amgen Inc.'s blockbuster Enbrel (etanercept) to treat arthritis. Read More

Regulators increasingly focused on Halal product certification for 2B Muslims

HONG KONG – Regulators around the world – beyond Muslim countries in Asia and the Middle East – are increasingly exploring the impact of Sharia Law on the health care markets they oversee. Read More

Financings

Aquinox Pharmaceuticals Inc., of Vancouver, British Columbia, said it intends to offer and sell $75 million of its common stock in an underwritten public offering. Read More

Stock movers

Read More

Appointments and advancements

Oncosec Medical Inc., of San Diego, named Sheela Mohan-Peterson chief legal and compliance officer. Read More

Other news to note

Epirus Biopharmaceuticals Inc., of Boston, said it entered an agreement for the acquisition of Bioceros Holding B.V., of Utrecht, the Netherlands, enabling the expansion of its biosimilar pipeline and vertical integration product development capabilities. Read More

In the clinic

Pherecydes Pharma SA, of Romainville, France, said it launched the Phagoburn trial, a randomized and monitored phase I/II, single-blind trial, to evaluate the tolerance and effectiveness of two anti-infection bacteriophage treatments in serious burn patients. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe